Kuei-Chuan Lee

Dr. Kuei-Chuan Lee


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
KLKuei-Chuan Lee
Kuei-Chuan Lee
PWPei-Shan Wu
Pei-Shan Wu
HLHan-Chieh Lin
Han-Chieh Lin
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes lipid accumulation. Lipotoxicity, oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress would further contribute to hepatocyte injury and death, leading to inflammation and immune dysfunction in the liver. During the healing process, the accumulation of an excessive amount of fibrosis might occur while healing. During the development of NASH and liver fibrosis, the gut-liver axis, adipose-liver axis, and renin-angiotensin system (RAS) may be dysregulated and impaired. Translocation of bacteria or its end-products entering the liver could activate hepatocytes, Kupffer cells, and hepatic stellate cells, exacerbating hepatic steatosis, inflammation, and fibrosis. Bile acids regulate glucose and lipid metabolism through Farnesoid X receptors in the liver and intestine. Increased adipose tissue-derived non-esterified fatty acids would aggravate hepatic steatosis. Increased leptin also plays a role in hepatic fibrogenesis, and decreased adiponectin may contribute to hepatic insulin resistance. Moreover, dysregulation of peroxisome proliferator-activated receptors in the liver, adipose, and muscle tissues may impair lipid metabolism. In addition, the RAS may contribute to hepatic fatty acid metabolism, inflammation, and fibrosis. The treatment includes lifestyle modification, pharmacological therapy, and non-pharmacological therapy. Currently, weight reduction by lifestyle modification or surgery is the most effective therapy. However, vitamin E, pioglitazone, and obeticholic acid have also been suggested. In this review, we will introduce some new clinical trials and experimental therapies for the treatment of NASH and related fibrosis.

1 October 2012 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
YHYun-Cheng Hsieh
Yun-Cheng Hsieh
CCChun-Ku Chen
Chun-Ku Chen
CSChien-Wei Su
Chien-Wei Su
CCChe-Chang Chan
Che-Chang Chan
THTeh-Ia Huo
Teh-Ia Huo
HLHan-Chieh Lin
Han-Chieh Lin

1 July 2015 in Medicine
Verified
Journal Article
Open access
CCChung-Kai Chou
Chung-Kai Chou
KLKuei-Chuan Lee
Kuei-Chuan Lee
CCChe-Chang Chan
Che-Chang Chan
CPChin-Lin Perng
Chin-Lin Perng
CCChun-Ku Chen
Chun-Ku Chen
HLHan-Chieh Lin
Han-Chieh Lin
The optimal timing of percutaneous cholecystostomy for severe acute cholecystitis is unclear. The aim of this study was to investigate the timing of percutaneous cholecystostomy and its relationship to clinical outcomes in patients with inoperable acute severe cholecystitis. From 2008 to 2010, 209 consecutive patients who were admitted to our hospital due to acute cholecystitis and were treated by percutaneous cholecystostomy were retrospectively reviewed. The time periods from symptom onset to when percutaneous cholecystostomy was performed and when patients were discharged were recorded. In the 209 patients, the median time period between symptom onset and percutaneous cholecystostomy was 23 hours (range, 3–95 hours). The early intervention group (≤24 hours, n = 109) had a significantly lower procedure-related bleeding rate (0.0% vs 5.0%, P = 0.018) and shorter hospital stay (15.8 ± 12.9 vs 21.0 ± 17.5 days) as compared with the late intervention group (>24 hours, n = 100). Delayed percutaneous cholecystostomy was a significant independent factor for a longer hospital stay (odds ratio 3.03, P = 0.001). In inoperable patients with acute severe cholecystitis, early percutaneous cholecystostomy reduced hospital stay and procedure-related bleeding without increasing the mortality rate.

30 November 2020 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
PLPei‐Chang Lee
Pei‐Chang Lee
YHYun‐Chen Hsieh
Yun‐Chen Hsieh
THTeh‐Ia Huo
Teh‐Ia Huo
UYUeng‐Cheng Yang
Ueng‐Cheng Yang
CLChao‐Hsiung Lin
Chao‐Hsiung Lin
KLKuei-Chuan Lee
Kuei-Chuan Lee

1 August 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KLKuei-Chuan Lee
Kuei-Chuan Lee
YHYun-Cheng Hsieh
Yun-Cheng Hsieh
CCChe-Chang Chan
Che-Chang Chan
HSHao-Jhe Sun
Hao-Jhe Sun
YHYi-Hsiang Huang
Yi-Hsiang Huang
HLHan-Chieh Lin
Han-Chieh Lin

1 January 2021 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
YHYun-Cheng Hsieh
Yun-Cheng Hsieh
KLKuei-Chuan Lee
Kuei-Chuan Lee
HLHao-Jan Lei
Hao-Jan Lei
KLKeng-Hsin Lan
Keng-Hsin Lan
THTeh-Ia Huo
Teh-Ia Huo
HLHan-Chieh Lin
Han-Chieh Lin
Activation of the (pro)renin receptor (PRR) upregulates the expression of profibrotic genes in the kidney and heart. We aimed to investigate the role of PRR in hepatic fibrogenesis. Human hepatic PRR levels were measured in patients with or without liver fibrosis. PRR expression was analyzed in primary mouse hepatic stellate cells (HSCs). Experimental fibrosis was studied in thioacetamide (TAA)-treated or methionine choline-deficient (MCD) diet-fed C57BL/6 mice. Lentivirus-mediated PRR short hairpin RNA (shRNA) was used to knockdown hepatic PRR expression. Lentiviral vectors expressing PRR shRNA or cDNA from the α-smooth muscle actin promoter were used for myofibroblast-specific gene knockdown or overexpression. PRR is upregulated in human and mouse fibrotic livers, and in activated HSCs. Hepatic PRR knockdown reduced liver fibrosis by suppressing the activation of HSCs and expression of profibrotic genes in TAA or MCD diet-injured mice without significant changes in hepatic inflammation. Renin and prorenin increased the expression of PRR and production of TGF-β1 in human activated HSC LX-2 cells, and knockdown of PRR inactivated LX-2 cells with decreased production of TGF-β1 and Smad3 phosphorylation. Myofibroblast-specific PRR knockdown also attenuated liver fibrosis in TAA or MCD diet-injured mice. Mice with both myofibroblast-specific and whole liver PRR knockdown showed downregulation of the hepatic ERK/TGF-β1/Smad3 pathway. Myofibroblast-specific PRR overexpression worsened TAA-induced liver fibrosis by upregulating the ERK/TGF-β1/Smad3 pathway. PRR contributes to liver fibrosis and HSC activation, and its downregulation attenuates liver fibrosis through inactivation of the ERK/TGF-β1/Smad3 pathway. Therefore, PRR is a promising therapeutic target for liver fibrosis.